HUMAN IMMUNOGLOBULINS
Agammaglobulinemia
Grifols Therapeutics LLCother_biologicalPhase 3Dormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Agammaglobulinemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
20-valent pneumococcal conjugate vaccine University of Alabama at Birmingham | Phase 4 | BB |
HUMAN IMMUNE GLOBULIN G Rutgers, The State University of New Jersey | Phase 1 | NR |
Same molecule, other indications
HUMAN IMMUNOGLOBULINS is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →